SAN DIEGO , June 3, 2015 / PRNewswire / -- aTyr Pharma, Inc. (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced the Company's participation at the 35 th Annual William Blair Growth Stock

SAN DIEGO , May 12, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), today announced the closing of its initial public offering of 6,164,000 shares of its common stock at an initial public offering price of $14.00 per share, before underwriting discounts, including 804,000 shares of

SAN DIEGO, May 6, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), today announced the pricing of its initial public offering of 5,360,000 shares of its common stock at an initial public offering price of $14.00 per share.  In addition, aTyr has granted the underwriters a

Designation recognizes the company's first Physiocrine-based drug candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD)   PR Newswire SAN DIEGO   SAN DIEGO, April 27, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and

Clinician and industry veteran brings experience in enzyme replacement therapies PR Newswire SAN DIEGO SAN DIEGO, April 27, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases,

PR Newswire SAN DIEGO   SAN DIEGO, April 9, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that it has named Marcy Graham as Vice President, Investor

PR Newswire SAN DIEGO and HONG KONG   SAN DIEGO and HONG KONG, April 6, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced that it has filed a

PR Newswire SAN DIEGO SAN DIEGO, Feb. 18, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug

First Physiocrine-Based Therapeutic Administered to Patients   PR Newswire SAN DIEGO SAN DIEGO, Jan. 28, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today

- Industry Veteran Established Immunology Research Programs at NovoNordisk, ZymoGenetics - Discovered Foxp3 Gene Critical for Regulating Immune Function   PR Newswire SAN DIEGO and HONG KONG SAN DIEGO and HONG KONG, Nov. 3, 2014 / PRNewswire / -- aTyr Pharma ("aTyr"), an innovative rare